333 reports of this reaction
5.9% of all DESMOPRESSIN ACETATE reports
#1 most reported adverse reaction
HYPONATRAEMIA is the #1 most commonly reported adverse reaction for DESMOPRESSIN ACETATE, manufactured by Ferring Pharmaceuticals Inc.. There are 333 FDA adverse event reports linking DESMOPRESSIN ACETATE to HYPONATRAEMIA. This represents approximately 5.9% of all 5,690 adverse event reports for this drug.
Patients taking DESMOPRESSIN ACETATE who experience hyponatraemia should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
HYPONATRAEMIA is moderately reported among DESMOPRESSIN ACETATE users, representing a notable but not dominant share of adverse events.
In addition to hyponatraemia, the following adverse reactions have been reported for DESMOPRESSIN ACETATE:
The following drugs have also been linked to hyponatraemia in FDA adverse event reports:
HYPONATRAEMIA has been reported as an adverse event in 333 FDA reports for DESMOPRESSIN ACETATE. This does not prove causation, but indicates an association observed in post-market surveillance data.
HYPONATRAEMIA accounts for approximately 5.9% of all adverse event reports for DESMOPRESSIN ACETATE, making it one of the most commonly reported side effect.
If you experience hyponatraemia while taking DESMOPRESSIN ACETATE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.